Maurizio Giorelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maurizio Giorelli has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Eleonora Pagano
Experimental Biology and Medicine Institute, CONICET, Buenos Aires, Argentina
1 shared publicationFelicia Ricchiuti
Department of Neurologic and Psychiatric Sciences, University of Bari, Bari, Italy
1 shared publicationGiovanni Defazio
Department of Neurologic and Psychiatric Sciences, University of Bari, Bari, Italy
1 shared publication- Maria Trojano
Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy
1 shared publication - Paolo Livrea
Department of Neurological and Psychiatric Sciences University of Bari Bari Italy
1 shared publication
Latest Publications
- 2 October 2001
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 21 (10) , 809-812
IFN- β 1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms
Recently, mRNA encoding soluble isoforms of CD28 and CTLA-4 have been described in human lymphocytes. We demonstrate that interferon-beta1a (IFN-beta1a) can enhance the expression of these transcripts in human mononuclear cells. Because soluble CD28 and CTLA-4 molecules might affect T cell activation, our findings suggest an additional means whereby IFN-beta therapy might exert its immunomodulatory effects in multiple sclerosis (MS).
- 2 October 2001
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 21 (10) , 809-812
IFN- β 1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms
Recently, mRNA encoding soluble isoforms of CD28 and CTLA-4 have been described in human lymphocytes. We demonstrate that interferon-beta1a (IFN-beta1a) can enhance the expression of these transcripts in human mononuclear cells. Because soluble CD28 and CTLA-4 molecules might affect T cell activation, our findings suggest an additional means whereby IFN-beta therapy might exert its immunomodulatory effects in multiple sclerosis (MS).